KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Jazz Pharmaceuticals (JAZZ) over the last 12 years, with Q3 2025 value amounting to $400.0 million.

  • Jazz Pharmaceuticals' Change in Acquisitions & Divestments rose 1267.61% to $400.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 8260.87%. This contributed to the annual value of $845.0 million for FY2024, which is 21296.3% up from last year.
  • Jazz Pharmaceuticals' Change in Acquisitions & Divestments amounted to $400.0 million in Q3 2025, which was up 1267.61% from $470.0 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Change in Acquisitions & Divestments peaked at $760.0 million during Q1 2021, and registered a low of $20.0 million during Q3 2023.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $300.0 million (2024), whereas its average is $287.5 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Change in Acquisitions & Divestments skyrocketed by 167500.0% in 2024, and later surged by 1267.61% in 2025.
  • Jazz Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $335.0 million in 2021, then plummeted by 82.09% to $60.0 million in 2022, then surged by 316.67% to $250.0 million in 2023, then grew by 16.0% to $290.0 million in 2024, then soared by 37.93% to $400.0 million in 2025.
  • Its last three reported values are $400.0 million in Q3 2025, $470.0 million for Q2 2025, and $310.0 million during Q1 2025.